Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction
Year: 2019
Type: article
Source: JACC Heart Failure
Institutions: Rigshospitalet, Baker Heart and Diabetes Institute, Northwestern University, Mayo Clinic, Cardiovascular Research Foundation, Wake Forest University Health Sciences, Wake Forest University, University Medical Center Groningen, National University of Singapore, National University Heart Centre Singapore, Duke-NUS Medical School, National Heart Centre Singapore, Wroclaw Medical University, University of Glasgow, Odense University Hospital
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Ironwood Pharmaceuticals, Incorporated, MyoKardia, Abiomed, Lundbeckfonden, Novo Nordisk, Astellas Pharma, Servier, National Institutes of Health, Medical Research Council, National Health and Medical Research Council, National Heart, Lung, and Blood Institute, Daiichi Sankyo Europe
Awards: G1149427950, HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction, Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and Phenomics, Mayo Heart Failure Regional Clinical Center, G3359795052, Machine learning for the automated identification and tracking of rare myocardial diseases, G6221860048, G7297454555, Determinants, Trajectories, and Consequences of Abnormal Cardiac Mechanics
OpenAlex ID: W2920988382